Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major

Anil Pathare, Ali Taher, Shahina Daar

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0%; P=0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0%; P=0.001), and mean liver iron concentration from 24.2±9.0 to 17.6± 12.9 mg Fe/g dry weight (-27.1%; P=0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalAnnals of Hematology
Volume89
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

beta-Thalassemia
Iron
Siderosis
Magnetic Resonance Imaging
Chelation Therapy
Iron Overload
Ferritins
Weights and Measures
deferasirox
Liver
Serum
Therapeutics

Keywords

  • β-thalassemia
  • Iron chelation
  • Iron overload
  • Magnetic resonance imaging
  • Myocardial iron
  • T2*

ASJC Scopus subject areas

  • Hematology

Cite this

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major. / Pathare, Anil; Taher, Ali; Daar, Shahina.

In: Annals of Hematology, Vol. 89, No. 4, 04.2010, p. 405-409.

Research output: Contribution to journalArticle

@article{fd008fea0d284569b772c3d5cff2b740,
title = "Deferasirox (Exjade{\circledR}) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major",
abstract = "Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0{\%}; P=0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0{\%}; P=0.001), and mean liver iron concentration from 24.2±9.0 to 17.6± 12.9 mg Fe/g dry weight (-27.1{\%}; P=0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of",
keywords = "β-thalassemia, Iron chelation, Iron overload, Magnetic resonance imaging, Myocardial iron, T2*",
author = "Anil Pathare and Ali Taher and Shahina Daar",
year = "2010",
month = "4",
doi = "10.1007/s00277-009-0838-z",
language = "English",
volume = "89",
pages = "405--409",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major

AU - Pathare, Anil

AU - Taher, Ali

AU - Daar, Shahina

PY - 2010/4

Y1 - 2010/4

N2 - Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0%; P=0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0%; P=0.001), and mean liver iron concentration from 24.2±9.0 to 17.6± 12.9 mg Fe/g dry weight (-27.1%; P=0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of

AB - Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with β-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean ± standard deviation cardiac T2* from a baseline of 17.2±10.8 to 21.5±12.8 ms (+25.0%; P=0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0%; P=0.001), and mean liver iron concentration from 24.2±9.0 to 17.6± 12.9 mg Fe/g dry weight (-27.1%; P=0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of

KW - β-thalassemia

KW - Iron chelation

KW - Iron overload

KW - Magnetic resonance imaging

KW - Myocardial iron

KW - T2

UR - http://www.scopus.com/inward/record.url?scp=77649296214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649296214&partnerID=8YFLogxK

U2 - 10.1007/s00277-009-0838-z

DO - 10.1007/s00277-009-0838-z

M3 - Article

C2 - 19798501

AN - SCOPUS:77649296214

VL - 89

SP - 405

EP - 409

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -